undamentalytics Newsletter

Rocket Pharmaceuticals, Inc. valuation and forecast

Explore the models for Rocket Pharmaceuticals, Inc., adjust their assumptions and compare your own valuation with the platform's.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Rocket Pharmaceuticals, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: limited reported history: available models are shown without a Buy/Hold/Sell rating. We'll show the comparison once resolved.

Analyst recommendations

14 analysts, Oct 2026
Buy750%
Hold643%
Sell17%

Monthly trend

  1. Oct 2026166114
  2. Sep 20261651114
  3. Aug 2026661114
  4. Jul 2026661114

Counts of recommendations published by analysts covering Rocket Pharmaceuticals, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Price history

Loading chart…

Third-party market data · may be delayed

RCKT valuation questions

How does Fundamentalytics value Rocket Pharmaceuticals, Inc.?
We use the models that fit Rocket Pharmaceuticals, Inc.'s business and available financial data. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.

Data: SEC EDGAR filings, retrieved Invalid Date. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Rocket Pharmaceuticals, Inc.